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Longitudinal analysis of varicella-zoster virus-specific antibodies in
systemic lupus erythematosus: No association with subclinical viral
reactivations or lupus disease activity
C Rondaan1, CC van Leer2, S van Assen3, H Bootsma1, K de Leeuw1, S Arends1, NA Bos1 and J Westra1
1Department of Rheumatology and Clinical Immunology, University Medical Centre Groningen, University of Groningen, The Netherlands;
2Department of Medical Microbiology (Clinical Virology), University Medical Centre Groningen, University of Groningen, Groningen,
The Netherlands; and 3Department of Internal Medicine (Infectious Diseases), Treant Care Group, Hoogeveen, The Netherlands
Systemic lupus erythematosus (SLE) patients are at high risk of herpes zoster. Previously, we
found increased immunoglobulin (Ig)G levels against varicella-zoster virus (VZV) in SLE
patients compared to controls, while antibody levels against diphtheria and cellular immunity
to VZV were decreased. We aimed to test our hypothesis that increased VZV-IgG levels in
SLE result from subclinical VZV reactivations, caused by stress because of lupus disease
activity or immunosuppressive drug use.
Methods: Antibody levels to VZV (IgG, IgA, IgM), total IgG and VZV-DNA were longitu-
dinally determined in the serum of 34 SLE patients, using enzyme-linked immunosorbent
assay and polymerase chain reaction. Clinical data were retrieved from medical records.
Reactivation of VZV was defined as an at least fivefold rise in VZV-IgG or presence of
VZV-IgM or VZV-DNA. Generalized estimating equations (GEE) were used to longitudinally
analyse associations between antibody levels, lupus disease activity and medication use.
Systemic Lupus Erythematosus Disease Activity Index, anti-double-stranded DNA and com-
plement levels were used as indicators of lupus disease activity. Results: A VZV reactivation
was determined in 11 patients (33%). In at least five of them, herpes zoster was clinically overt.
No association between SLE disease activity or medication use and VZV-specific antibody
levels was found. There was a weak association between total IgG and VZV-IgG. Conclusions:
Our results indicate that increased VZV-IgG levels in SLE do not result from frequent
subclinical VZV reactivations, and are not associated with lupus disease activity. Increased
VZV-IgG can only partially be explained by hypergammaglobulinaemia. Lupus (2018) 0, 1–8.
Key words: Systemic lupus erythematosus; infection; humoral immunity; varicella-zoster virus;
herpes zoster; immunosuppression
Introduction
Infectious diseases are an important cause of mor-
bidity and mortality in patients with systemic lupus
erythematosus (SLE), an autoimmune disease that
is characterized by the presence of autoantibodies
and recurrent disease ﬂares.1 Herpes zoster (HZ),
characterized by severe pain and rash in a
dermatomal distribution, is one of the infectious
diseases frequently aﬀecting SLE patients. The inci-
dence of HZ is reported to be 5 to 16 times higher
in SLE patients than in the general population, and
is associated with the use of immunosuppressive
medication.2–5
HZ is caused by reactivation of the varicella-
zoster virus (VZV). After primary infection, known
as varicella or chickenpox, VZV establishes latency
in the sensory nerve ganglia.6–8 Since almost the
entire population of temperate countries has experi-
enced a primary VZV infection in childhood, almost
the entire adult population is at risk of HZ, occur-
ring when cellular immunity to VZV wanes.9
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Previously, we found increased VZV-speciﬁc anti-
body levels of the immunoglobulin (Ig) G class in
SLE patients compared to age-matched healthy
controls, while cellular immunity to VZV was
found to be decreased. This phenomenon could
not be explained by polyclonal hypergammaglobu-
linaemia alone, which is often observed in SLE,
because for diphtheria lower antibody levels were
found in SLE patients than in age-matched healthy
controls.10
Similar to VZV, increased antibody levels to
other human herpes viruses, such as Epstein-Barr
virus (EBV) and cytomegalovirus (CMV) have been
described in SLE.11 Antibody levels to several other
infectious agents were shown not to diﬀer or even
be lower in SLE patients, compared to healthy con-
trols.12 Human herpes viruses, in particular EBV,
have been implicated to play a role in the develop-
ment and relapsing course of SLE.13
Over the years, diﬀerent research groups have
suggested that reactivation of VZV without overt
clinical manifestations may play a role in the
increased VZV-IgG level in SLE patients.10,14,15
Indeed, it is known that a clinically evident reacti-
vation of VZV, herpes zoster, leads to long-lasting
increases in VZV-speciﬁc IgG levels.16,17 Subclinical
reactivations of VZV have been described in
immunocompromised patients18 and are known to
occur under stressful circumstances, even in other-
wise healthy individuals.19,20
In the present study antibody levels to VZV and
presence of VZV-DNA were determined longitu-
dinally in a retrospective cohort of SLE patients.
We expected to ﬁnd frequent subclinical VZV
reactivations in SLE patients, able to account for
their increased VZV antibody levels. We hypothe-
sized that VZV reactivations in SLE patients would
be potentiated by stress because of SLE disease
activity or immunosuppressive drug use, and
aimed to investigate the association between VZV
reactivation, VZV antibody levels, lupus disease
activity and immunosuppressive drug use.
Materials and methods
Study population
Serum samples, present in our biobank, from ran-
domly selected SLE patients were used. Patients
could be included in the study when they fulﬁlled
American College of Rheumatology (ACR) criteria
for SLE21 and had a minimum age of 18 years at
time of ﬁrst serum sample. At least ﬁve samples per
patient had to be present, with a minimum of one
year between ﬁrst and last sample. The study has
been carried out in accordance with the principles
of the Declaration of Helsinki. Approval by the
medical ethics committee of the University
Medical Centre Groningen was obtained and all
patients gave informed consent.
Definition of VZV reactivation
In line with the deﬁnition of Ljungman et al.,18 a
subclinical reactivation was deﬁned as an at least
ﬁvefold increase in VZV-speciﬁc IgG antibody
level or the occurrence of speciﬁc IgM (unless
explained by presence of rheumatoid factor) without
clinical signs of varicella or zoster. Moreover, we
added the occurrence of VZV-DNA in serum to
the existing deﬁnition. The deﬁnition of a clinical
reactivation was the same as that of a subclinical
one, but in the presence of clinical symptoms of
herpes zoster. As VZV-speciﬁc IgA has been sug-
gested to have some value in the diagnosis of
herpes zoster,16 we also analysed the course of anti-
bodies of this isotype, but did not include it in the
deﬁnition of a VZV reactivation.
VZV-specific antibody levels
For determining VZV-speciﬁc IgG, IgA and IgM
levels, an in-house glycoprotein enzyme-linked
immunosorbent assay (ELISA) was performed,
which was validated previously.10 VZV-puriﬁed
glycoproteins (EastCoast Bio, North Berwick, ME,
USA) were used as antigen, and pooled human
serum with known levels of anti-glycoprotein VZV
was used as standard. Threshold for positivity was
set at 100 mIU/ml for VZV-speciﬁc IgG levels, at 50
U/ml for VZV-speciﬁc IgA levels and at 15 U/ml for
VZV-speciﬁc IgM levels, according to recommenda-
tions of a commercial kit used for validating the
in-house ELISAs (Institut Virion\Serion).
Detection of VZV-DNA
DNA was extracted from whole blood samples by
the MagnaPure 96 system, using the MagnaPure 96
DNA and viral DNA small volume kit (Roche
Applied Bioscience, Mannheim, Germany) accord-
ing to the manufacturer’s instructions. Detection of
VZV-DNA was performed using a previously
described protocol.22
Total IgG antibody levels
Total IgG antibody levels were determined using a
commercial kit (Thermo Fisher Scientiﬁc, Waltham,
MA, USA), following the manufacturer’s instructions.
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Symptoms of herpes zoster
Medical records from included patients were
checked for a history of herpes zoster during the
follow-up period and at least two years before the
ﬁrst sample, when possible.
Statistics
Generalized estimating equations (GEE) were used
to explore parameters associated with antibody levels
over time. The exchangeable correlation matrix was
used to take into account the within-patient correl-
ations. In case residuals were non-normally distribu-
ted, the dependent variable was log-transformed
before being entered into the analysis. Tested param-
eters included disease activity and immunosuppres-
sive medication use over time. Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI,
continuous and 5 for active disease), anti-double-
stranded DNA (anti-dsDNA) and complement levels
(C3, C4) were used as indicators of lupus disease
activity. Medication use was tested overall (use of
any immunosuppressive drugs) and for diﬀerent
drugs separately when used by at least ﬁve patients.
Lastly, longitudinal associations between VZV-IgG
and total IgG were investigated.
To be able to compare results from this study
with results from studies using a cross-sectional
sample, statistical analyses were also conducted
when including the ﬁrst available patient samples
only. Associations between antibody levels (VZV-
speciﬁc IgG and IgA, and total IgG), patient char-
acteristics, medication use and disease activity par-
ameters were explored by determining Spearman’s
correlations coeﬃcients in case of continuous vari-
ables and using the Mann–Whitney U test to com-
pare diﬀerences between groups.
Statistical analysis was performed using IBM
SPSS Statistics 23 (SPSS, Chicago, IL, USA).
Figures were created using GraphPad Prism 5.0
(GraphPad Software, La Jolla, CA, USA). P
values 0.05 were considered signiﬁcant.
Results
Patient characteristics
Thirty-four SLE patients were eligible based on the
inclusion criteria. One of these patients was found to
be VZV seronegative and was therefore excluded from
further analysis. Characteristics of the remaining 33
SLE patients are summarized in Table 1, including
an overview of immunosuppressive medication use.
Longitudinal measurement of total IgG antibodies
and VZV-specific antibodies
There was considerable variation in levels of
VZV-speciﬁc IgG and total IgG between patients.
Twenty-eight of 33 patients exceeded the normal
upper limit of 16.0g/l of total IgG at one or multiple
times during follow-up. A total of 17 (52%) SLE
patients had positive VZV-speciﬁc IgA levels
(50U/ml) at one or multiple time points during
follow-up (data not shown). In two (6%) patients,
levels of VZV-speciﬁc IgM above the threshold
for positivity (15U/ml) were found that could not
be explained by presence of rheumatoid factor (data
not shown).
Reactivations of VZV
A total of 11 patients (33%) had a VZV reactiva-
tion during follow-up, according to the predeﬁned
deﬁnition (see Methods) (Table 2). There were no
patients with multiple VZV reactivations during the
follow-up period. Patient characteristics, including
disease activity and medication use, from patients
who experienced a VZV reactivation did not diﬀer
from those who did not (data not shown). When
reviewing medical records from all patients, clinic-
ally overt herpes zoster episodes were found in ﬁve
patients, all of which met the predeﬁned deﬁnition
of reactivation (Table 2).
Table 1 Patient characteristics
Total n¼ 33
Female gender, no. (%) 29 (88)
Age at baseline (years), median (range) 39.2 (18.2–75.6)
Disease duration at baseline (months), median (range) 71.3 (0–272.2)
Follow-up duration (months), median (range) 41.4 (14.5–58.2)
Serum samples per patient, median (range) 11 (5–17)
Patients with active disease (SLEDAI 5 at any point
during follow-up), no. (%)
23 (70)
Number of periods with SLEDAI score 5 in patients
with active disease, median (range)
1 (1–4)
Immunosuppressive medication use at any time during
follow-up, no. (%) j newly started or dose increase
during follow-up, no. (%)
Overall 33 (100)
Prednisone 26 (79) j 20 (61)
Hydroxychloroquine 22 (67) j 11 (33)
Azathioprine 17 (52) j 9 (27)
Mycophenolate mofetil 10 (30) j 7 (21)
Cyclophosphamide 5 (15) j 5 (15)
Methotrexate 3 (9) j 1 (3)
Cyclosporine 1 (3) j 0 (0)
Ocrelizumaba 1 (3) j 1 (3)
aUsed in a study setting.
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.
Longitudinal analysis of VZV-Ig in SLE
C Rondaan et al.
3
Lupus
In three patients (SLE3, SLE17 and SLE26)
VZV reactivation was closely related to a change
in medication (Table 2).
Supplementary ﬁgures of antibody levels, pres-
ence of VZV-DNA and anti-dsDNA (as a measure
of lupus disease activity) for all patients with a VZV
reactivation are available online.
Increases in VZV-specific IgG antibody level
Six patients had a 5-fold rise in VZV-speciﬁc IgG
level (Table 2). Total IgG levels were stable at the
time of VZV-speciﬁc IgG increases, indicating that
large increases in VZV-speciﬁc IgG levels were not
a consequence of increases in total IgG levels (data
not shown).
In four of six patients with a VZV-IgG increase,
clinical complaints matching herpes zoster were evi-
dent when reviewing medical records. For a ﬁfth
patient (SLE26), the VZV-IgG increases occurred
during a severe SLE ﬂare including skin manifest-
ations and herpes zoster-like complaints could not
be distinguished with certainty from the medical
records retrospectively.
Figure 1 shows the last sample before a 5-fold
VZV-speciﬁc IgG increase and course thereafter.
Interestingly, VZV-speciﬁc IgG levels remained at
increased levels for a long time and had not
returned to original level after one year.
Presence of VZV-DNA in serum
VZV-DNA was detected in the serum of ﬁve
patients. In two of those patients (SLE2 and
SLE3) a 5-fold VZV-speciﬁc IgG level increase
also was seen and they had clinically evident
herpes zoster. In another patient (SLE34) a
drop of VZV-speciﬁc IgG was seen at the time of
VZV-DNA presence.
Presence of VZV-specific IgM antibodies
In two patients positive VZV-speciﬁc IgM levels
were found. Patient SLE23 had a very high VZV-
speciﬁc IgM value of 479U/ml at one time point,
rapidly decreasing at succeeding time points.
Patient SLE6 had positive but decreasing VZV-spe-
ciﬁc IgM levels at the start of follow-up that lasted
for over one year. At the same time VZV-speciﬁc
















SLE2 3 3 3 3 10 months prior: Start of azathioprine
SLE3 3 3 3 3 Three months prior: Start of ocrelizumab and
mycophenolate mofetil, increase in prednisone
dose from 2.5 to 15mg daily
SLE5 3 3 3 Stable for 18 months
SLE6 3 No medication use at time of VZV-IgM
positivity
SLE15 3 3 3 No medication use prior to HZ
SLE17 3 Two months prior: restart prednisolone
SLE23 3 Stable for over one year
SLE26 3 Unsure. At time
of SLE flare.
One month prior: Start of mycophenolate
mofetil, increase in prednisone dose
SLE27 3 3 Stable for at least two years
SLE33 3 3 Stable
SLE34 Drop in VZV-IgG 3 3 3 Stable
ID: identification; VZV: varicella-zoster virus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; HZ: herpes zoster; IgG: immuno-
globulin G.
Figure 1 Last sample before 5-fold rise and the varicella-
zoster virus (VZV)-specific immunoglobulin G (IgG) course
thereafter in five systemic lupus erythematosus (SLE) patients,
presented on a log-scale. Because the VZV-IgG rise in patient
SLE5 occurred in the last sample, this patient is not included in
the graph.
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IgG levels gradually decreased. No clinical signs of
a VZV reactivation were present in these patients.
Presence of VZV-specific IgA antibodies
Levels of VZV-IgA above the threshold for positiv-
ity were found in 17 patients. The ﬁve patients with
clinically evident herpes zoster all were VZV-IgA
positive at that time. A rise in VZV-IgG usually
co-occurred with a rise in VZV-IgA.
Longitudinal analysis of VZV-specific antibody
levels
VZV-IgG levels were stable following SLE disease
ﬂare (including 11 patients with a minimum
diﬀerence in SLEDAI of four points between inter-
vals) (Figure 2).
Moreover, GEE analysis showed no signiﬁcant
associations between VZV-speciﬁc IgG levels and
parameters of disease activity, including SLEDAI
(continuous and 5 for active disease), levels of
anti-dsDNA, and C3 and C4 levels (Table 3).
After excluding patients with a 5-fold rise in
VZV-IgG level (n¼ 6), eliminating the possibly dis-
torting eﬀects of such a large increase to be able to
assess the association between smaller variations in
VZV-IgG and total IgG levels, a weak but statis-
tically signiﬁcant association was seen (B 0.008,
95% conﬁdence interval 0.001–0.016, p¼ 0.025).
Signiﬁcant but very weak associations were
revealed between VZV-speciﬁc IgA levels and
anti-dsDNA levels or VZV-speciﬁc IgG levels
using GEE (data not shown).
Parameters associated with total IgG levels over time
GEE analysis of variables of inﬂuence on total IgG
levels was performed as a large variation was
observed in total IgG levels between patients and
also within patients over time, and a weak associ-
ation between VZV-IgG and total IgG levels
seemed to be present. This analysis revealed that
overall medication use was inversely associated
with total IgG levels. A negative association was
shown for the use of prednisone, mycophenolate
mofetil and cyclophosphamide.
C3 and C4 were also negatively associated with
total IgG levels. As C3 and C4 are known to indi-
cate active disease when decreased, this inverse
Table 3 GEE analysis exploring the relationship of disease activity and medication use with
VZV-IgG levels (log-transformed) over time in all patients and in patients without 5-fold
rise in VZV-IgG
B (95% CI) p
SLEDAI –0.010 (–0.031 to 0.010) 0.315
Active disease (SLEDAI 5) –0.031 (–0.116 to 0.053) 0.468
Anti-dsDNA 9.45 10–5 (–1.92 10–4 to 3.81 10–4) 0.518
C3 0.123 (–0.241 to 0.486) 0.509
C4 0.033 (–0.972 to 1.038) 0.949
Medication use
Overall (use vs. no use) –0.001 (–0.108 to 0.107) 0.992
Prednisone (dose in mg/day) –0.003 (–0.007 to 0.002) 0.240
Hydroxychloroquine (use vs. no use) –0.036 (–0.120 to 0.049) 0.411
Azathioprine (dose in mg/day) –0.001 (–0.002 to 0.001) 0.442
Mycophenolate mofetil (use vs. no use) 0.227 (–0.086 to 0.539) 0.155
Cyclophosphamide (use vs. no use) –0.244 (–0.545 to 0.057) 0.113
Total IgG levels 0.006 (–0.003 to 0.015) 0.216
GEE: generalized estimating equations; CI: confidence interval; SLEDAI: Systemic Lupus
Erythematosus Disease Activity Index; C3: complement 3; C4: complement 4; dsDNA: double-stranded
DNA; IgG: immunoglobulin G; VZV: varicella-zoster virus.
Figure 2 Stable course of varicella-zoster virus (VZV)-
immunoglobulin G (IgG) surrounding systemic lupus erythe-
matosus (SLE) disease flare in 11 patients with a minimum
difference in Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI) of four points between intervals.
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association indicates that patients with active dis-
ease have higher total IgG levels. This is in line with
the positive association between total IgG levels
and other measures of disease activity: SLEDAI
(continuous and score 5 for active disease) and
anti-dsDNA levels (Table 4).
Cross-sectional analysis using first available samples
To be able to compare our results with previous
studies that used a cross-sectional approach, we
analysed the ﬁrst included samples per patient in
a cross-sectional manner. In this analysis, a signiﬁ-
cant correlation between VZV-speciﬁc IgG and IgA
levels was found (rho¼ 0.404), but not between
VZV-IgG and total IgG. Another signiﬁcant but
inverse correlation was determined between VZV-
speciﬁc IgG levels and C4 levels (rho¼ –0.360). No
signiﬁcant correlations between other parameters
and VZV-IgG levels were found. For VZV-IgA
levels, no signiﬁcant correlations were noted with
parameters other than VZV-IgG. Signiﬁcant nega-
tive correlations were demonstrated between total
IgG levels and prednisone dose (rho¼ –0.612) and
C3 levels (rho¼ –0.459).
Discussion
The present study was initiated to clarify the cause
of the elevated VZV-speciﬁc IgG levels in SLE
patients. During longitudinal observation, in which
33 VZV-seropositive SLE patients were followed for
a median duration of 41.4 months, one substantial
(5 fold) VZV-IgG increase was observed without
clinical symptoms of herpes zoster. It therefore
seems unlikely that subclinical VZV reactivations
play an important causative role in the origin of
increased VZV-IgG levels in SLE. Furthermore, lon-
gitudinal analysis using GEE did not reveal an asso-
ciation between lupus disease activity or medication
use and VZV-speciﬁc antibody levels.
In three patients we found a subclinical reacti-
vation (one positive VZV-IgM, two presence of
VZV-DNA) while VZV-IgG remained stable.
Substantial increases in VZV-speciﬁc IgG level
were shown in six patients, almost all coinciding
with clinical symptoms matching herpes zoster, as
assessed retrospectively by reviewing medical rec-
ords. The increased VZV-IgG levels were shown
to be long lasting, with high levels even after a
year of follow-up. Also, in healthy individuals
VZV-speciﬁc IgG is known to remain increased
for months and even one year after herpes
zoster.16,17
Medication use was found not to be associated
with VZV-speciﬁc IgG levels over time, but was
clearly shown to be negatively associated with
total IgG levels. Although in three patients a
close temporal relationship was seen between the
start of a new drug and a VZV-reactivation, num-
bers are too low to draw ﬁrm conclusions.
When patients with a large increase in VZV-spe-
ciﬁc IgG values were excluded from the analysis, a
weak association between VZV-speciﬁc IgG and
total IgG levels was revealed that was not found
in the cross-sectional analysis. This suggests that
there can be some inﬂuence of general increased
B-cell activity on the height of VZV-IgG values,
but that this association is insuﬃcient to completely
explain the increased height of VZV-speciﬁc IgG
values in SLE patients.
Table 4 GEE analysis exploring the relationship of disease activity and medication use with
total IgG levels in all patients
B (95% CI) p
SLEDAI 0.389 (0.070 to 0.707) 0.017
Active disease (SLEDAI 5) 2.182 (0.323 to 4.04) 0.021
Anti-dsDNA 0.005 (0.001 to 0.009) 0.011
C3 –6.872 (–9.923 to –3.821) <0.0005
C4 –19.830 (–32.661 to –6.998) 0.002
Medication use
Overall (use vs. no use) –3.779 (–5.763 to –1.795) <0.0005
Prednisone (dose in mg/day) –0.236 (–0.302 to –0.170) <0.0005
Hydroxychloroquine (use vs. no use) –0.210 (–2.178 to 1.759) 0.835
Azathioprine (dose in mg/day) –0.502 (–2.940 to 1.937) 0.687
Mycophenolate mofetil (use vs. no use) –4.922 (–8.046 to –1.799) 0.002
Cyclophosphamide (use vs. no use) –4.529 (–5.343 to –3.714) <0.0005
GEE: generalized estimating equations; C3: complement 3; C4: complement 4; CI: confidence interval;
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; dsDNA: double-stranded DNA; IgG:
immunoglobulin G. Significant associations are presented in bold.
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Our ﬁndings add valuable information to the
debate on the role of human herpes viruses in the
development and relapsing course of SLE. EBV
especially has been implicated to be involved.13
Increased antibody levels and impaired cellular
immunity to EBV in SLE patients.23,24 were
found, similar to our previous ﬁndings for VZV.10
The elevated level of antibodies directed against
lytic cycle antigens and an elevated level of EBV-
DNA are suggested to indicate frequent EBV
reactivations, and to contribute to the occurrence
of SLE disease ﬂares.23 However, there is no direct
evidence of this proposed link. The lack of an asso-
ciation between SLE disease activity and VZV
reactivations in our study suggests that there is no
etiologic role of VZV reactivations in the relapsing
disease course of SLE. Further research is needed
to investigate whether this also holds true for other
human herpes viruses.
Although herpes zoster is usually diagnosed
based on clinical symptoms, the diagnosis can be
challenging, when rash is absent (e.g. zoster sine
herpete, VZV encephalitis). Elevated levels of
VZV-speciﬁc IgA have been proposed to be of
some diagnostic value in these cases.16,25 VZV-spe-
ciﬁc IgA positivity was found in 17 out of 33 SLE
patients at one or multiple time points during
follow-up in our study, while only ﬁve patients
were found to have clinically evident herpes
zoster. The value of VZV-IgA in diagnosing
herpes zoster therefore is questionable in SLE
patients. VZV-speciﬁc IgM was shown to lack sen-
sitivity when assessing its value in the diagnosis of
herpes zoster in SLE patients.
This study has some limitations. Most import-
ant, because of the retrospective study design, clin-
ical data regarding herpes zoster complaints could
be missing from hospital medical records, as herpes
zoster infections do not necessarily come to the
attention of the treating specialist. Also, the study
population consisted of patients with established
disease, which made it impossible to study possible
alterations in VZV-speciﬁc humoral immunity ear-
lier in the disease course. Furthermore, the deﬁn-
ition of a subclinical reactivation is arbitrary and
intervals between measurements were not standar-
dized. We believe we have used a broad deﬁnition,
based on the study by Ljungman et al.,18
including 5-fold VZV-IgG increases, positivity
of IgM and the addition of VZV-DNA.
A strength of the study is the use of GEE ana-
lysis in looking for associations between VZV anti-
body levels, disease activity and medication
use. The GEE analysis was independent from the
arbitrary deﬁnition of subclinical reactivation and
this type of analysis is suitable for analyses of data
with non-standardized intervals.
Concluding, our study results do not support
the hypothesis that the increased VZV-speciﬁc
antibody levels in SLE patients are caused by sub-
clinical VZV reactivations or are related to SLE
disease activity or medication use during estab-
lished disease. Although generally increased B-cell
activity seems to inﬂuence the height of VZV-IgG
values, this association is insuﬃcient to completely
explain the increased height of VZV-speciﬁc IgG
values. Our ﬁndings might suggest an origin earlier
in the disease process. Despite the limitation of a
retrospective design, this study adds to the under-
standing of the humoral response to VZV in this
patient group at increased risk of herpes zoster.
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